ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI
The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.
Highlighted Terms
Related News
The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.